title: Non-stem cell origin for oligodendroglioma.
abstract: Malignant astrocytic brain tumors are among the most lethal cancers. Quiescent and therapy-resistant neural stem cell (NSC)-like cells in astrocytomas are likely to contribute to poor outcome. Malignant oligodendroglial brain tumors, in contrast, are therapy sensitive. Using magnetic resonance imaging (MRI) and detailed developmental analyses, we demonstrated that murine oligodendroglioma cells show characteristics of oligodendrocyte progenitor cells (OPCs) and are therapy sensitive, and that OPC rather than NSC markers enriched for tumor formation. MRI of human oligodendroglioma also suggested a white matter (WM) origin, with markers for OPCs rather than NSCs similarly enriching for tumor formation. Our results suggest that oligodendroglioma cells show hallmarks of OPCs, and that a progenitor rather than a NSC origin underlies improved prognosis in patients with this tumor.
authors.affiliation: Department of Neurology, University of California, San Francisco, 94158, USA.
authors.forename: Anders I
authors.initials: AI
authors.lastname: Persson
authors.forename: Claudia
authors.initials: C
authors.lastname: Petritsch
authors.forename: Fredrik J
authors.initials: FJ
authors.lastname: Swartling
authors.forename: Melissa
authors.initials: M
authors.lastname: Itsara
authors.forename: Fraser J
authors.initials: FJ
authors.lastname: Sim
authors.forename: Romane
authors.initials: R
authors.lastname: Auvergne
authors.forename: David D
authors.initials: DD
authors.lastname: Goldenberg
authors.forename: Scott R
authors.initials: SR
authors.lastname: Vandenberg
authors.forename: Kim N
authors.initials: KN
authors.lastname: Nguyen
authors.forename: Stanislava
authors.initials: S
authors.lastname: Yakovenko
authors.forename: Jennifer
authors.initials: J
authors.lastname: Ayers-Ringler
authors.forename: Akiko
authors.initials: A
authors.lastname: Nishiyama
authors.forename: William B
authors.initials: WB
authors.lastname: Stallcup
authors.forename: Mitchel S
authors.initials: MS
authors.lastname: Berger
authors.forename: Gabriele
authors.initials: G
authors.lastname: Bergers
authors.forename: Tracy R
authors.initials: TR
authors.lastname: McKnight
authors.forename: Steven A
authors.initials: SA
authors.lastname: Goldman
authors.forename: William A
authors.initials: WA
authors.lastname: Weiss
mesh_terms: D000818:Animals; D000941:Antigens / Q000032:analysis; D001549:Benzamides / Q000494:pharmacology; D001932:Brain Neoplasms / Q000473:pathology*; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D058953:Neural Stem Cells / Q000473:pathology*; D009836:Oligodendroglia / Q000473:pathology*; D009837:Oligodendroglioma / Q000473:pathology*; D018739:Oncogene Proteins v-erbB / Q000032:analysis; D011509:Proteoglycans / Q000032:analysis; D000077204:Temozolomide; D016159:Tumor Suppressor Protein p53 / Q000502:physiology; D000099216:Chondroitin Sulfate Proteoglycan 4
chemical_list: D000941:Antigens; D001549:Benzamides; D003606:Dacarbazine; D004159:Diphenylamine; D020928:Mitogen-Activated Protein Kinases; D018739:Oncogene Proteins v-erbB; D011509:Proteoglycans; D000077204:Temozolomide; D016159:Tumor Suppressor Protein p53; D000099216:Chondroitin Sulfate Proteoglycan 4; C506614:mirdametinib